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Abstract
BACKGROUND—Results of previous single center observational studies suggest that daily 
bathing of patients with chlorhexidine may prevent hospital-acquired bloodstream infections 
(HABSIs) and acquisition of multidrug-resistant organisms (MDROs).
METHODS—We conducted a multicenter, cluster randomized, non-blinded crossover trial to 
evaluate the effect of daily bathing with chlorhexidine impregnated washcloths on the acquisition 
of MDROs and incidence of HABSIs. Nine intensive care and bone marrow transplant units in 6 
hospitals were randomly assigned to bathe patients with either 2% no-rinse chlorhexidine-
impregnated or non-antimicrobial washcloths for a six-month period, exchanged for the alternate 
product during the subsequent six months. The incidence rates of acquisition of MDRO and 
HABSI rates were compared between the two time periods by Poisson regression analysis.
RESULTS—A total of 7735 patients were enrolled during the study. The overall MDRO 
acquisition rate was 21% lower when chlorhexidine bathing was used (5.10 cases per 1000 patient 
days) than when non-antimicrobial washcloths were used (6.60 cases per 1000 patient days, 
p=0.028). The overall HABSI rate was 31% lower when chlorhexidine was used (4.45 cases per 
1000 patient days) than when non-antimicrobial cloths were used (6.60 cases per 1000 patient 
days, p=0.007) No serious skin reactions were noted in either study period.
CONCLUSIONS—Daily bathing with chlorhexidine-impregnated washcloths significantly 
reduced the risk of acquiring MDROs and developing HABSI.
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Introduction
Multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant enterococcus (VRE), have become endemic in 
many acute and long term care facilities (1–5). Infections caused by these organisms are 
often difficult to treat due to a dwindling armamentarium of active antimicrobials. The 
Centers for Disease Control and Prevention (CDC) has promulgated a variety of strategies 
including hand hygiene and use of isolation precautions to limit the spread of these 
organisms between patients, but these require consistent adherence to practices by large 
numbers of healthcare personnel during frequent patient encounters, and can be difficult to 
sustain. (6) In addition, healthcare-associated infections (HAI) associated with these and 
other microorganisms (7, 8) inflict considerable morbidity and mortality and incur 
substantial excess costs that in some cases are no longer reimbursed by third party payers, 
including the Centers for Medicare and Medicaid Services (CMS)(9, 10). Targeted 
interventions, particularly in intensive care units, can substantially reduce the risk of 
hospital-acquired bloodstream infections (HABSIs) associated with the use of central 
venous catheters. Several large studies have demonstrated that improving catheter insertion 
processes, including standardizing the use of insertion site antisepsis with chlorhexidine-
containing products, can decrease infection risks (11–13). However, the use of antiseptic 
agents for patient bathing is currently considered controversial.
Chlorhexidine gluconate (CHG) is an antiseptic that has broad spectrum activity against 
many organisms, including Staphylococcus aureus and Enterococcus spp. Unlike many other 
antiseptics, CHG has residual antibacterial activity, making it ideal for decreasing microbial 
burden on patients’ skin and preventing secondary environmental contamination. Vernon et 
al. found that daily bathing with CHG-impregnated cloths decreased VRE skin 
contamination by 2.5 logs compared to soap and water bathing, as well as decreasing VRE 
contamination of healthcare workers’ hands by 40% and environmental surfaces by 30% 
(14). By controlling the source, these investigators reduced patient acquisition of VRE by 
66%.
Because HABSIs often result from the ingress of skin organisms into the bloodstream along 
vascular catheters or other breaks in skin integrity, skin decontamination could theoretically 
also decrease HABSI risk. Bleasdale et al. showed that daily bathing with 2% CHG-
impregnated cloths reduced the incidence of primary BSI by 60% (15). Our previous 
observational study evaluating CHG bathing in six ICUs demonstrated a 66% reduction in 
VRE bacteremia (16). Previous studies evaluating CHG bathing have been mainly single-
center, “before and after” observational studies, limiting the general applicability of results. 
We therefore conducted a multicenter, randomized cluster trial to evaluate the utility of CHG 
bathing to reduce MDRO acquisition and HABSI risks for patients at high risk for HAI.
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Materials and Methods
Study Design
We performed a multicenter, cluster randomized crossover study involving patients 
hospitalized in intensive care or bone marrow transplant units between August 2007 and 
February 2009. Units were randomized to either perform daily bathing of patients with non-
antimicrobial washcloths (control) [Comfort Bath, SAGE Products, Inc.] or washcloths 
impregnated with 2% CHG (intervention) [2% Chlorhexidine Gluconate Cloth Patient 
Preoperative Skin Preparation, SAGE Products inc.] during the initial 6-month study period, 
followed by daily bathing with the alternate product for the second six-month period. The 
order in which units were assigned to the control or intervention arms was stratified by unit 
type and by facility. The investigators and clinical staff were not blinded to the use of control 
or intervention bathing.
Before the study was initiated, nurses were educated on the proper techniques for bathing 
patients with both washcloth products. Skin care products not compatible with CHG were 
eliminated prior to study initiation. Nursing personnel monitored patients for skin reactions 
and reported them to the investigators who graded skin reactions on a scale of 1–4 based on 
severity and determined whether reactions were attributable to bathing.
All units performed active surveillance testing (AST) for MRSA and VRE throughout the 
study period. Unit staff obtained nares (MRSA) and peri-rectal (VRE) swabs form patients 
≤48 hours after unit admission and on unit discharge. The microbiology laboratories at each 
institution processed surveillance specimens using either standard culture-based or 
molecular-based (PCR) identification of MRSA and VRE. All patients found to be colonized 
or infected with MRSA and or VRE were placed on contact precautions once test results 
became available. Patients with a previous history of MRSA or VRE were placed on contact 
precautions upon admission.
Each participating unit submitted at least ten separate MRSA and VRE isolates obtained 
from unit patients to the coordinating center each month for CHG susceptibility testing. 
Susceptibility testing was completed by the agar dilution method with CHG concentrations 
ranging from 0.1 μg/ml to 1024 μg/ml (17).
The work was supported by the Centers for Disease Control Prevention and by SAGE 
Products, Inc. SAGE Products, Inc. supplied CHG-impregnated and non-antimicrobial 
washcloths to participating units for the duration of the study, provided technical and 
educational support and participated in weekly teleconferences with the Study Group during 
the conduct of the studybut was not involved in study design, analysis or preparation of this 
manuscript. Approval was obtained from individual center and CDC institutional review 
boards (IRBs). Waiver of written informed consent was obtained at each institution based on 
the minimal risk nature of the study. Patients who refused participation were not bathed with 
CHG-impregnated washcloths. The study was registered with clinicaltrials.gov 
(NCT00502476).
Climo et al. Page 3
N Engl J Med. Author manuscript; available in PMC 2017 November 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Definitions
Incident and prevalent cases of MRSA or VRE were classified as previously described (16). 
Bloodstream infections (BSI) were identified using National Healthcare Safety Network 
(NHSN] definitions (18). HABSI were defined as BSI detected >48 hours after unit 
admission. Primary BSI were defined as HABSI detected > 48 hours without an attributable 
secondary infection source. Central line-associated bloodstream infections (CLABSI) were 
defined as primary BSI in a patient with at least one central venous catheter in place within 
48 hours of BSI detection.
Statistical Analysis
We evaluated changes in the mean MRSA and VRE acquisition and HABSI rates. We tested 
the null hypothesis that the rates during the control period equaled the rates during the 
intervention period using PROC GENMOD in SAS (version 8.2, Cary, NC) to fit a Poisson 
regression model that accounts for monthly MRSA and VRE prevalence in each unit as 
possible confounders.
We used a Cox proportional-hazards regression model to compare the time from admission 
until the first primary BSI between the control and intervention groups. We calculated the 
survival time as: 1) the interval between admission and discharge from the study unit for 
those patients who did not acquire primary BSI and as 2) the interval between admission and 
the first positive culture for patients with primary BSI.
We examined the impact of these unit characteristics on primary BSI rates: unit size, unit 
type, mean length of stay, utilization rate of central venous catheters, median patient age, 
distribution of patient gender, monthly incident MRSA ratemonthly incident VRE rate 
prevalence rate of MRSA at admission, and prevalence rate of VRE at admission. We 
compared changes in the incidence rates of primary BSI between the control period and 
intervention periods. Continuous variables were examined using two sample t tests and 
linear regression modeling and categorical variables were examined by Fisher’s exact test.
Treatment Interruption
On June 28th, 2008 SAGE Products, Inc. initiated a nationwide recall of the 2% CHG-
impregnated washcloths, because of Burkholderia cepacia contamination of some product 
lots. Units using the CHG product at the time of the recall were switched to non-
antimicrobial washcloths and local and CDC IRBs were immediately notified. Following 
remediation and approval of IRBs, use of the CHG product was resumed. Data from units 
assigned to CHG bathing during the recall period were censored from the final analysis.
Results
Twelve units from seven hospitals were recruited to participate in the planned 12-month 
study. One unit withdrew from the study and two units were eliminated from the analysis 
because of low compliance with the study protocol. The final nine study units included 
medical, coronary care, surgical, and cardiac surgery ICUs and one bone marrow transplant 
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unit (Table 1). Patient participation refusal rate was low (<0.5%) and data from all patients 
admitted to participating units were included in an intention to treat analysis.
Acquisition of MRSA and VRE
During the periods when non-antimicrobial cloths were used, 165 new cases of MRSA or 
VRE acquisition were detected compared with 127 during the CHG bathing periods. The 
overall MRSA or VRE acquisition rate was 23% lower during the intervention period (Table 
2; 5.10 vs. 6.60 cases per 1000 patient days; P=0.028). Reductions in the incidence of VRE 
and MRSA acquisition were unrelated to the monthly prevalence of either MRSA or VRE.
The overall VRE acquisition rate was 27% lower during the intervention compared to 
control periods (3.21 vs. 4.28 cases per 1000 patient days, p= 0.052). The overall MRSA 
acquisition rate was 19% lower during the intervention period, but this difference did not 
reach statistical significance (1.89 vs. 2.32 cases per 1000 patient days, p=0.29)
Bloodstream Infections
Overall, 165 HABSIs were detected among patients during the control period compared to 
119 HABSIs during the intervention period. The HABSI rate was 30% lower during 
intervention compared to control periods (4.78 vs. 6.60 cases per 1000 patient days; 
p=0.007, Table 2.), reflecting the 31% lower primary BSI rate during intervention compared 
to control periods (3.61 vs. 5.24 cases per 1000 patient days; p=0.006) and the CLABSI rate 
was 51% lower during the intervention compared to control periods (1.55 vs. 3.30 cases per 
1000 catheter days; p=0.004). The rate of secondary BSI did not differ significantly between 
the intervention and the control periods.
Based on Cox proportional-hazards survival regression analysis, the risk of acquiring a 
primary BSI was significantly lower among patients bathed with CHG than among those 
bathed with the non-antimicrobial cloths (p=0.016, Figure 1). This effect was greatest 
among patients with longer lengths of unit stay. Patients with lengths of unit stay >7 days 
who were bathed with chlorhexidine were 0.69 times less likely to acquire a primary BSI 
compared with patients bathed with CHG (RR=0.69, 95% CI 0.47–0.99). Patients with 
lengths of unit stay >14 days who were bathed with chlorhexidine were 0.51 times less 
likely to acquire a primary BSI (RR 0.51, 95% CI 030–0.87).
Among the 221 primary BSIs, staphylococci (30%), gram-negative bacilli (23%), 
enterococci (20%), and yeast and fungi (12%) were the most common pathogens (Table 3). 
The incidence rate of primary BSI caused by coagulase-negative staphylococci was 56% 
lower during the intervention periods than during the control periods (0.60 vs. 1.36 cases per 
1000 patient days, p=0.008). Similarly, the incidence rate of primary BSIs caused by fungi 
was 53% lower during the intervention compared to control periods but this did not reach 
statistical significance (0.36 cases per 1000 patient days vs. 0.76 cases per 1000 patient days, 
p=0.06).
The incidence of CLABSI caused by gram-positive organisms (0.89 vs. 1.76 cases per 1000 
line days, p=0.05) and by fungi (0.07 vs. 0.77 cases per 1000 line days, p<0.001) were 
significantly lower during intervention periods. Overall, the incidence of CLABSI-
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associated fungemia was 90% lower during intervention periods. CHG bathing was not 
associated with a significant reduction in incidence of CLABSI caused by gram-negative 
organisms or VRE or MRSA BSI, likely related to the low number of infections caused by 
these organisms.
Due to concerns that the interruption of treatment may have affected the observed outcomes, 
we performed additional analysis of the BSI incidence rates including those months when 
non-antimicrobial cloths were used by units affected by the national recall. Addition of data 
obtained during the 4 months of treatment interruption when only non-antimicrobial bathing 
cloths were used did not alter the BSI analysis results. In this analysis, 58 months of use of 
non-antimicrobial cloths for bathing was compared to 54 months of 2% chlorhexidine cloth 
use. The overall results remained the same. The overall incidence of HABSIs was decreased 
in those months where chlorhexidine was in use (6.32 vs 4.78, p= 0.018).
Unit Characteristics
Reductions in primary BSI rates were highest among MICUs. The primary BSI rate in 
MICUs was 40% lower during the intervention compared to control periods (3.98 vs 6.62 
cases per 1000 patient days). In contrast, the primary BSI rate in other units was 17% lower 
during the intervention periods than during the control periods (3.10 vs. 3.73 cases per 1000 
patient days) (figure 1). However, the observed reductions in primary BSIs among MICUs 
was not statistically significantly associated with the unit type. Other unit characteristics--
unit size, mean length of stay, baseline primary BSI rate, median age of patients, MRSA and 
VRE prevalence, catheter utilization, and gender distribution--were not associated with 
changes in the rates of primary BSI.
Chlorhexidine Susceptibility
We performed antimicrobial susceptibility on clinical isolates collected during the entire 
study period. We tested a total of 1106 VRE and MRSA isolates for susceptibility to 
chlorhexidine by the agar dilution method. Chlorhexidine was slightly more active against 
MRSA with an MIC90 of 4 μg/ml compared an MIC90 of 8 μg/ml for VRE isolates.
Adverse Reactions
CHG bathing was well tolerated. The overall incidence of skin reactions among patients 
assigned to CHG bathing was 1.9% (78/3973 patients) compared to 3.4% (130/3857 
patients) among patients assigned to bathing with the control product. All 208 reported skin 
reactions were felt to be unrelated to the bathing intervention and overall 85% were 
classified as mild to moderate in nature (grade 1 or 2).
Discussion
Our study, the first multicenter cluster randomized study evaluating daily CHG bathing, 
confirmed the results of prior single center trials suggesting that CHG bathing reduces 
transmission of resistant organisms and HABSI risk among intensive care and bone marrow 
transplant unit patients (14–16, 19, 20). In addition, the participation of facilities from 
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different U.S. geographic regions supports the generalizability of these results to other 
academic medical centers.
Our results support the findings of Bleasdale et al. and Vernon et al. and suggest that CHG 
bathing may be particularly effective at reducing BSI risk among ICU patients (14, 15). In 
contrast to these previous studies that involved a limited number of units, our multicenter 
design allowed a more robust examination of whether the reductions in BSIs were related to 
the type of unit. We found no statistically significant interaction between the type of unit and 
the development of BSIs suggesting that chlorhexidine bathing may be beneficial in many 
unit settings. In addition, CHG bathing may be particularly beneficial for patients with long 
ICU stays.
Our study also had some unanticipated findings. First, CHG bathing was associated with 
lower rates of CLABSI-associated fungemia. Previous studies have found lower risks for 
gram-positive CLABSI associated with CHG bathing (14–16) but have not reported reduced 
fungemia rates. CHG has biphasic fungicidal activity (21) but topical use of CHG has not 
been suggested as a possible intervention to reduce in the incidence of fungemia among 
patients with indwelling central lines. Previous efforts to reduce the incidence of fungemia 
have relied mostly on systemic antifungal prophylaxis, which can increase the incidence of 
antifungal resistance among fungal isolates (22). If our results are confirmed, topical use of 
CHG could be added to strategies to prevent fungal infections.
The use of chlorhexidine bathing was associated with significant reductions in the incidence 
of gram positive bacteremias, similar to previous studies. The majority of these reductions 
were related to the reductions seen among coagulase negative staphylococci. Despite the 
overall reduction in the acquisition of MRSA and VRE, significant reductions in the 
incidence of MRSA and VRE bacteremias were not seen. This was likely related to the 
overall low number of hospital acquired bacteremias due to these two organisms.
We did not identify any serious adverse effects associated with daily CHG bathing. Serious 
allergic reactions have been reported with the topical use of CHG but these reactions appear 
to be rare (23–26). We did not detect the emergence of MRSA or VRE isolates with high-
level CHG resistance during the study. Concerns for increased resistance to biocides and 
disinfectants like CHG among nosocomial bacteria have tempered enthusiasm for wider 
adoption of their use in hospitals for skin antisepsis (27–34). However, the potential for 
emergence of CHG resistance remains a substantial concern and should be monitored over 
time (35).
Identifying simple, cost-effective, and safe strategies for HAI prevention is essential. Daily 
bathing with CHG-impregnated washcloths is a strategy that is relatively straightforward to 
implement and sustain because it does not require a significant change from patient bathing 
practices that are currently routine. We demonstrated that this intervention was associated 
with lower MRSA and VRE acquisition rates and decreased HABSI rates. The results of this 
multicenter cluster randomized study strongly suggest that daily CHG bathing can be an 
important weapon in the ongoing battle to prevent HAIs and improve patient safety.
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Figure 1. Reductions in primary bloodstream infections observed with the use of daily 
chlorhexidine bathing
Incidence rates of hospital acquired primary bloodstream infections are shown among units 
utilizing daily bathing with either Chlorhexidine impregnated washcloths (black) or non-
antimicrobial washcloths (gray).
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Figure 2. Kaplan–Meier Estimates of Time to Primary Bloodstream Infections
The cumulative probability of developing a primary bloodstream infection is compared for 
patients who received Chlorhexidine based bathing (gray) to Controls (Black). The overall 
protective efficacy of chlorhexidine bathing was 30% (p=0.0158). The inset graph shows a 
more detailed version of the larger graph with a probability up to 0.25.
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Table 2
Effect of Daily Chlorhexidine Bathing on the Incidence of Hospital-acquired Bloodstream Infections and 
Acquisition of the Multi-drug Resistant Organisms, MRSA and VRE
Intervention Period Control Period p value
Admissions (n) 3,970 3,842 0.32
Gender
 Male (%) 61.3 60.8 0.63
 Female (%) 38.7 39.2 0.63
Bed Days of Care 24,902 24,983 0.85
Central line days 13,425 13,049 0.14
Mean Length of Stay (days) 6.35 6.39 0.53
MRSA prevalencea 13.8% 12.8% 0.14
VRE prevalencea 16.3% 15.1% 0.24
MDRO Acquisition (n) 127 165
 Incidence rated 5.10 6.60 0.028
VRE Acquisition (n) 80 107
 Incidence rateb 3.21 4.28 0.052
MRSA Acquisition (n) 47 58
 Incidence rateb 1.89 2.32 0.29
Total Hospital Acquired BSIs (n) 119 165
 Incidence Rateb 4.78 6.60 0.007
Total Primary BSIs (n) 90 131
 Incidence rateb 3.61 5.24 0.006
Catheter Associated BSIs (n) 21 43
 Incidence Ratec 1.55 3.30 0.004
Secondary BSIs (n) 29 34
 Incidence Rateb 1.20 1.40 0.45
a
Total number of prevalent cases per 100 patients admitted to study unit
b
Total number of cases per 1000 patient days
c
Total number of cases per 1000 device days
d
Total number of acquired cases of MRSA or VRE among eligible patients per 1000 patient days
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